PV Bulletin

Vislyfa (ranibizumab) Authorized in the European Union

Vislyfa, containing ranibizumab, has been authorized for use in the EU, effective from July 15, 2026.

Primary source: View

PV Impact Brief

Urgency: HighConfidence: high

What changed

Vislyfa has been granted marketing authorization in the EU, establishing its status for medical use and initiating safety monitoring protocols.

Why it matters

Authorization of Vislyfa strengthens treatment options for patients with retinal diseases and mandates ongoing monitoring for adverse reactions, operationalizing the safety evaluation framework.

Action needed

Implement resource allocation for increased monitoring of reported adverse reactions specific to Vislyfa as per the new safety evaluation requirements.

Relevant for
Labeling Lead
Processes impacted
Labeling
Owner

Regulatory Intelligence Lead

Review cadence

Review in the next regulatory intelligence cycle.

Evidence and confidence

Confidence: highSource updated: Sep 8, 2026

Full briefing

Practical implication

Implement resource allocation for increased monitoring of reported adverse reactions specific to Vislyfa as per the new safety evaluation requirements.

The European Medicines Agency has officially authorized Vislyfa, a biosimilar to Lucentis, for the treatment of certain retinal diseases in adults, effective from July 15, 2026. This authorization includes specific guidelines on usage and monitoring.

What changed: Vislyfa has been granted marketing authorization in the EU, establishing its status for medical use and initiating safety monitoring protocols.

Why it matters: Authorization of Vislyfa strengthens treatment options for patients with retinal diseases and mandates ongoing monitoring for adverse reactions, operationalizing the safety evaluation framework.

Practical implication: Implement resource allocation for increased monitoring of reported adverse reactions specific to Vislyfa as per the new safety evaluation requirements.

View original source

  • Source: EMA - What's new RSS
  • Published at source: 2026-09-08T00:00:00.000Z
  • Discovered by monitor: 2026-09-09T21:44:28.235Z

Published from the regulator source ingestion pipeline after PV impact triage.

#Labeling#Safety Signals#Source-ingestion#Regulator-monitor#European Union#Ema.europa.eu

Related updates for your role

publicEuropean Medicines Agency (EMA) · European Union · Updated Sep 8, 2026

EMA: Human medicines European public assessment report (EPAR): Benlysta, belimumab, Date of authorisation: 13/07/2011, Revision: 41, Status: Authorised Benlysta RSS Authorised This medicine is authorised for use in the European Union belimumab Medici

Urgency: High

Stakeholders must review and update the labeling of Benlysta in accordance with the new indications highlighted in the EPAR.

LabelingLabeling Lead
SOP Impact1 SOPs
ConfidenceHigh
Relevant for: Labeling Lead
verifiedRegulatory action: Regulators
Read impact briefarrow_forward
publicFDA · USA · Updated Sep 9, 2026

FDA grants accelerated approval to sevabertinib for non-squamous NSCLC

Urgency: High

Update labeling and handle regulatory documentation to reflect the new approved indication for sevabertinib, including dosage guidance of 20 mg orally twice daily.

LabelingSignal ManagementRegulatory Intelligence Lead
SOP Impact2 SOPs
ConfidenceHigh
Relevant for: Regulatory Intelligence Lead, Labeling Lead
verifiedRegulatory action: Regulators
Read impact briefarrow_forward
publicTherapeutic Goods Administration (TGA) · Australia · Updated Sep 8, 2026

Updated classification rules for certain combination products

Urgency: High

Review and adjust labeling and compliance processes for affected combination products as per the new regulations.

Country ComplianceLabelingRegulatory Intelligence Lead
SOP Impact2 SOPs
ConfidenceHigh
Relevant for: Regulatory Intelligence Lead, Labeling Lead
verifiedRegulatory action: Regulators
Read impact briefarrow_forward
publicEuropean Medicines Agency · European Union · Updated Sep 8, 2026Translated From German

Agenda of the CVMP meeting 8-10 September 2026

Monitoring

Stakeholders should prepare for discussions regarding veterinary medicinal product reviews, specifically focusing on maximum residue limits and ensure all interests are declared by participants.

LabelingRegulatory Intelligence Lead
SOP Impact1 SOPs
ConfidenceHigh
Relevant for: Regulatory Intelligence Lead
verifiedRegulatory action: Regulators
Read impact briefarrow_forward